Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1.
Our goal is to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases.
Following a recent Series B fundraise, and supported by both the Scottish Investment Bank and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology.
Medannex has been shortlisted as a finalist for both ‘Investment of the Year’ and ‘Outstanding Skills Development’ at Scotland’s Life Sciences Annual Awards 2020.